Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma

Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary endpoint was safety. Secondary endpoints included progression-free survival at 6 months (PFS-6), overall survival at 6 months (OS-6), and immune correlates of response. Results: CYT-101 T-cell therapy demonstrated polyfunctional activity, broad HLA restriction, potent cytolytic function, and diverse T-cell receptor repertoires. Nine patients received study treatment. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Only six adverse events were considered treatment-related, and no treatment-related serious adverse events, graft-versus-host disease, cytokine release syndrome, or neurotoxicity occurred. OS-6 and PFS-6 were 55% and 11%, respectively, with a median overall survival of 9.1 months. No objective clinical responses were seen. Of the nine treated participants, one had stable disease, five had progressive disease, and three were unevaluable by modified RANO criteria. Immune profiling revealed enhanced global CD4+ and CD8+ T-cell function following CYT-101 therapy, while donor-derived CYT-101 clonotypes were detected in six of nine participants, with significant T-cell repertoire remodelling. Conclusions: Allogeneic CMV-specific T-cell therapy combined with pembrolizumab was safe in recurrent GBM, supporting further evaluation of this strategy to overcome immune dysfunction in GBM.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.17.26367100
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma

Leone Beagley, Vivien Biggs, Adam Stirling, Rajiv Khanna et al.
medRxiv
Glioma Diagnosis and Treatment
preprint

Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma

Leone Beagley, Vivien Biggs, Adam Stirling, Rajiv Khanna, Archana Panikkar, Michelle A. Neller, Panteha Khaledi, Hilary Reddiex, Meggie Voogt, Jyothy Raju, Shannon Flynn, Matthew Solomon, Corey Smith, Paulo Martins, David Walker, Jessica Kelly, Hamish Alexander
preprint en

Abstract

Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary endpoint was safety. Secondary endpoints included progression-free survival at 6 months (PFS-6), overall survival at 6 months (OS-6), and immune correlates of response. Results: CYT-101 T-cell therapy demonstrated polyfunctional activity, broad HLA restriction, potent cytolytic function, and diverse T-cell receptor repertoires. Nine patients received study treatment. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Only six adverse events were considered treatment-related, and no treatment-related serious adverse events, graft-versus-host disease, cytokine release syndrome, or neurotoxicity occurred. OS-6 and PFS-6 were 55% and 11%, respectively, with a median overall survival of 9.1 months. No objective clinical responses were seen. Of the nine treated participants, one had stable disease, five had progressive disease, and three were unevaluable by modified RANO criteria. Immune profiling revealed enhanced global CD4+ and CD8+ T-cell function following CYT-101 therapy, while donor-derived CYT-101 clonotypes were detected in six of nine participants, with significant T-cell repertoire remodelling. Conclusions: Allogeneic CMV-specific T-cell therapy combined with pembrolizumab was safe in recurrent GBM, supporting further evaluation of this strategy to overcome immune dysfunction in GBM.

medRxiv
The University of Queensland (AU), QIMR Berghofer Medical Research Institute (AU)
Medical Research Future Fund
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon